Oncology News

Children with inherited liver disease who underwent liver transplantation for hepatocellular carcinoma had superior long-term survival compared with children without inherited liver disease and adults with inherited liver disease, according to a recently published study.

Direct-acting antiviral treatment for hepatitis C did not correlate with an increased risk for hepatocellular carcinoma in a large cohort study of both treated and untreated patients with or without cirrhosis. Those with incident HCC after DAA treatment had higher risk factors at baseline.

Elevated levels of hepatitis B DNA and hepatitis B surface antigen correlated significantly with an increased risk for liver cancer, according to recently published data.

Recently published data suggest that higher hepatocellular carcinoma incidence after sustained virologic response with interferon-free hepatitis C treatment correlates to patient baseline risk factors, such as age, Child-Turcotte Pugh score and prior treatment, rather than IFN-free therapy.

Single metabolic parameters are insufficient in evaluating risks for severe liver disease, according to a recently published study. Instead, researchers advised that a comprehensive risk assessment must include multiple factors of the metabolic syndrome and any alcohol use.

High perioperative levels of intra-platelet serotonin correlated with early disease recurrence after liver resection, while low levels increased the risk for postoperative morbidity, according to a recently published study.

Both caffeinated and decaffeinated coffee correlated with a lower risk for all-cause mortality and colorectal cancer-specific mortality after CRC diagnosis, according to recently published data.

Consuming coffee lowered the risk for death and a broad spectrum of health outcomes, according to a report recently published in BMJ.

Select patients with hepatocellular carcinoma who surpassed traditional indications for living donor liver transplantation exceeded survival expectations, with rates comparable to patients within the Milan criteria, according to results of a prospective study.

The Perlmutter Cancer Center at NYU Langone Health launched a new liver tumor program, designed to provide multidisciplinary care for patients with primary and secondary liver and bile duct cancers, according to a press release.